Panacea Biotec Stock Screener | Share Price & Fundamental Analysis
PANACEABIO
Pharmaceuticals
Screen Panacea Biotec share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹366.30
▼
-3.60 (-0.97%)
Share Price BSE
₹365.90
▼
-4.40 (-1.19%)
Market Cap
₹2,326.61 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
2.80
EPS (TTM)
₹-1.37
Dividend Yield
-
Debt to Equity
0.02
52W High
₹566.20
52W Low
₹297.25
Operating Margin
-13.00%
Profit Margin
-9.33%
Revenue (TTM)
₹150.00
EBITDA
₹-9.00
Net Income
₹-14.00
Total Assets
₹1,290.00
Total Equity
₹831.00
Panacea Biotec Share Price History - Stock Screener Chart
Screen PANACEABIO historical share price movements with interactive charts. Analyze price trends and patterns.
Panacea Biotec Company Profile - Fundamental Screener
Screen Panacea Biotec company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for PANACEABIO shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE922B01023
Panacea Biotec Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen PANACEABIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 1,290 | 1,241 | 1,271 | 1,759 | 1,178 | 1,390 | 1,376 | 1,608 | 1,800 | 1,854 |
| Current Assets | 545 | 486 | 562 | 951 | 511 | 683 | 508 | 560 | 533 | 549 |
| Fixed Assets | 567 | 582 | 600 | 622 | 609 | 657 | 806 | 949 | 1,001 | 1,071 |
| Liabilities | ||||||||||
| Total Liabilities | 1,290 | 1,241 | 1,271 | 1,759 | 1,178 | 1,390 | 1,376 | 1,608 | 1,800 | 1,854 |
| Current Liabilities | 92 | 94 | 101 | 109 | 960 | 743 | 90 | 611 | 846 | 930 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 831 | 838 | 840 | 874 | -232 | 196 | 347 | 306 | 366 | 450 |
| Share Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 22 |
| Reserves & Surplus | 807 | 814 | 816 | 849 | -257 | 139 | 335 | 293 | 340 | 426 |
Screen PANACEABIO income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 150 | 184 | 169 | 170 | 155 | 122 | 150 | 159 | 149 | 163 | 163 | 157 | 143 | 151 | 1,821 |
| Expenses | 159 | 168 | 159 | 156 | 140 | 130 | 143 | 151 | 147 | 140 | 135 | 124 | 109 | 191 | 171 |
| EBITDA | -9 | 16 | 9 | 14 | 14 | -8 | 8 | 8 | 2 | 24 | 29 | 33 | 34 | -40 | 1,650 |
| Operating Profit % | -13.00% | -1.00% | -20.00% | 5.00% | 5.00% | -12.00% | -4.00% | 0.00% | -2.00% | -8.00% | -4.00% | -8.00% | -4.00% | -72.00% | -21.00% |
| Depreciation | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 11 |
| Interest | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 31 |
| Profit Before Tax | -19 | 7 | 0 | 4 | 5 | -17 | -2 | -2 | -8 | 13 | 18 | 22 | 23 | -51 | 1,608 |
| Tax | -5 | 3 | 2 | 0 | 0 | -1 | 0 | 1 | 1 | 2 | 31 | 3 | 8 | 5 | 371 |
| Net Profit | -14 | 4 | -2 | 4 | 5 | -16 | -2 | -2 | -8 | 11 | -13 | 19 | 16 | -56 | 1,238 |
| EPS | -2.27 | 0.66 | -0.31 | 0.74 | 0.77 | -2.59 | -0.23 | -0.37 | -1.35 | 1.79 | -2.03 | 3.16 | 2.56 | -9.17 | 202.03 |
Panacea Biotec Cash Flow Screener - Liquidity Fundamentals
Screen PANACEABIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -27 | 4 | -423 | -108 | 107 | -31 | 105 | 118 | 131 | 91 |
| Investing Activities | 65 | 7 | 430 | 1,283 | -48 | -35 | -6 | 55 | -26 | 17 |
| Financing Activities | -3 | -3 | -18 | -1,176 | -47 | 91 | -101 | -164 | -107 | -117 |
| Net Cash Flow | 35 | 7 | -11 | -2 | 12 | 26 | -2 | 9 | -2 | -10 |
Screen PANACEABIO shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 72.48% | 72.48% | 72.48% | 73.59% | 73.46% | 72.87% | 72.49% | 73.59% |
| FII Holding | 1.16% | 0.78% | 1.06% | 0.27% | 0.27% | 0.37% | 0.38% | 0.00% |
| DII Holding | 1.49% | 1.52% | 1.81% | 0.84% | 1.07% | 1.16% | 1.17% | 0.43% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 18.45% | 18.17% | 17.69% | 19.90% | 20.42% | 18.11% | 18.98% | 15.82% |
| Other Holding | 6.41% | 7.05% | 6.96% | 5.40% | 4.79% | 7.49% | 6.99% | 10.16% |
| Shareholder Count | 33,593 | 34,256 | 33,593 | 46,242 | 45,513 | 39,982 | 35,446 | 48,634 |
Panacea Biotec Dividend Screener - Share Yield Analysis
Screen PANACEABIO dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Panacea Biotec Index Membership - Market Screener Classification
Screen PANACEABIO by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Panacea Biotec Market Events Screener - Corporate Actions
Screen PANACEABIO market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -4.67% | ||
| Annual General Meeting | NA | -17.99% | ||
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -6.47% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 7.49% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -1.52% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | 5.62% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | 12.32% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 0.00% |
Panacea Biotec Competitors Screener - Peer Comparison
Screen PANACEABIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 414,605 | 39.37 | 54,729 | 9.71% | 10,980 | 42.10 |
| Divis Laboratories | 169,701 | 67.76 | 9,712 | 18.67% | 2,191 | 48.20 |
| Torrent Pharmaceuticals | 131,496 | 60.85 | 11,539 | 6.99% | 1,911 | 67.66 |
| Cipla | 122,103 | 22.30 | 28,410 | 7.12% | 5,291 | 51.10 |
| Dr Reddys Laboratories | 104,838 | 18.24 | 33,741 | 16.73% | 5,725 | 45.31 |
| Lupin | 96,170 | 22.10 | 22,910 | 13.74% | 3,306 | 56.06 |
| Zydus Life Science | 92,262 | 18.30 | 23,511 | 18.55% | 4,615 | 45.37 |
| Mankind Pharma | 90,929 | 50.34 | 12,744 | 20.90% | 2,007 | 50.55 |
| Aurobindo Pharma | 70,591 | 20.25 | 32,346 | 9.43% | 3,484 | 56.45 |
| Alkem Laboratories | 66,867 | 27.11 | 13,458 | 3.70% | 2,216 | 50.91 |
Panacea Biotec Company Announcements - News Screener
Screen PANACEABIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-31 | Intimation Regarding Receipt Of Demand Order | View |
| 2025-12-31 | Closure of Trading Window | View |
| 2025-12-29 | Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order | View |
| 2025-12-15 | Authorization Of Key Managerial Personnel For The Purpose Of Determining Materiality Of An Event Or Information &Making Disclosures To The Stock Exchange(S) Under The SEBI LODR Regulations | View |
| 2025-12-15 | Appointment of Company Secretary and Compliance Officer | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Cessation | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-04 | Details Of Shares Dematerialized During November 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018 | View |
| 2025-11-26 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-26 | Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) | View |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-14 | Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-14 | Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-13 | Intimation Regarding Change In Senior Management Personnel In The CompanyS Material Wholly Owned Subsidiary Viz. Panacea Biotec Pharma Limited (PBPL) | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order | View |
| 2025-11-07 | Details Of Shares Dematerialized During October 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018 | View |
| 2025-11-06 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-11-04 | Board Meeting Intimation for Approving Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-09 | Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order | View |